Loading stock data…
Collegium Pharmaceutical (COLL)
$35.20-0.39 (-1.10%)
Market ClosedLast close Jul 24
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Collegium Pharmaceutical, Inc. in the Healthcare sector is trading at $35.20 with a market capitalization of $1.1B. Wall Street consensus targets $53.60 (5 analysts), implying a +52.3% move over the next 12 months. The stock is currently 31% below its 52-week high of $50.79, remaining 10.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +52.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $193.52M↓ | $205.45M↓ | $209.36M↑ | $188.00M↑ | $177.76M |
| Gross Profit | $117.25M↓ | $128.38M↓ | $129.17M↑ | $108.38M↑ | $97.32M |
| Operating Income | $30.90M↓ | $60.74M↓ | $62.07M↑ | $34.75M↑ | $20.90M |
| Net Income | $14.50M↓ | $16.96M↓ | $31.51M↑ | $11.98M↑ | $2.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.99%
Volume
Today's trading volume
243,522
Recent News
Is Collegium Pharmaceutical (COLL) Still Undervalued As Its Growth Narrative Holds Up?
Collegium Pharmaceutical Stock Update After Recent Trading Moves Collegium Pharmaceutical (COLL) has moved within a relatively tight range recently, with the stock down 0.5% over the last session but up in the past week and month. For investors tracking pain management specialists, Collegium Pharmaceutical’s roughly $1.2b market value, last close of $36.08, and 1-year total return of 15.6% set the stage for assessing whether current pricing aligns with its fundamentals. See our latest...
1 Healthcare Stock with Competitive Advantages and 2 We Question
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 11.9% over the past six months while the S&P 500 was up 8.7%.
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.